Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Among authors: kitano s. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print. Ophthalmology. 2023. PMID: 38158159 Free article.
Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer: a case report.
Xu S, Shukuya T, Shimamura S, Hayashi T, Sato Y, Shiozaki H, Nishioki T, Nishino K, Kato M, Hattori A, Shimada N, Suzuki K, Kitano S, Takahashi K. Xu S, et al. Among authors: kitano s. Transl Lung Cancer Res. 2024 Mar 29;13(3):666-672. doi: 10.21037/tlcr-23-765. Epub 2024 Mar 27. Transl Lung Cancer Res. 2024. PMID: 38601437 Free PMC article.
Investigation of recurrence prediction ability of EndoPredict® using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict® from microarray data from fresh-frozen to FFPE tissues.
Watanabe A, Tsunashima R, Kato C, Kitano S, Matsumoto S, Sota Y, Morita M, Sakaguchi K, Naoi Y. Watanabe A, et al. Among authors: kitano s. Breast Cancer. 2024 Apr 8. doi: 10.1007/s12282-024-01573-7. Online ahead of print. Breast Cancer. 2024. PMID: 38587783
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours.
Patel MR, Johnson M, Winer I, Arkenau HT, Cook N, Samouëlian V, Aljumaily R, Kitano S, Duffy C, Ge M, Elgadi M, Siu LL. Patel MR, et al. Among authors: kitano s. Cancer Immunol Immunother. 2024 Mar 30;73(5):89. doi: 10.1007/s00262-024-03654-0. Cancer Immunol Immunother. 2024. PMID: 38554156 Free PMC article. Clinical Trial.
Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
Fukuda H, Arai K, Mizuno H, Nishito Y, Motoi N, Arai Y, Hiraoka N, Shibata T, Sonobe Y, Kayukawa Y, Hashimoto E, Takahashi M, Fujii E, Maruyama T, Kuwabara K, Nishizawa T, Mizoguchi Y, Yoshida Y, Watanabe SI, Yamashita M, Kitano S, Sakamoto H, Nagata Y, Mitsumori R, Ozaki K, Niida S, Kanai Y, Hirayama A, Soga T, Tsukada K, Yabuki N, Shimada M, Kitazawa T, Natori O, Sawada N, Kato A, Yoshida T, Yasuda K, Ochiai A, Tsunoda H, Aoki K. Fukuda H, et al. Among authors: kitano s. Cancer Sci. 2024 Mar 25. doi: 10.1111/cas.16154. Online ahead of print. Cancer Sci. 2024. PMID: 38527308 Free article.
Investigating the immunological function of alpha-2-glycoprotein 1, zinc-binding in regulating tumor response in the breast cancer microenvironment.
Hanamura T, Yokoyama K, Kitano S, Kagamu H, Yamashita M, Terao M, Okamura T, Kumaki N, Hozumi K, Iwamoto T, Honda C, Kurozumi S, Richer JK, Niikura N. Hanamura T, et al. Among authors: kitano s. Cancer Immunol Immunother. 2024 Feb 13;73(3):42. doi: 10.1007/s00262-024-03629-1. Cancer Immunol Immunother. 2024. PMID: 38349455 Free PMC article.
1,187 results